JP2016514697A - 酸化ストレス障害の処置のためのフェナジン−３−オンおよびフェノチアジン−３−オン誘導体 - Google Patents

酸化ストレス障害の処置のためのフェナジン−３−オンおよびフェノチアジン−３−オン誘導体 Download PDF

Info

Publication number
JP2016514697A
JP2016514697A JP2016503226A JP2016503226A JP2016514697A JP 2016514697 A JP2016514697 A JP 2016514697A JP 2016503226 A JP2016503226 A JP 2016503226A JP 2016503226 A JP2016503226 A JP 2016503226A JP 2016514697 A JP2016514697 A JP 2016514697A
Authority
JP
Japan
Prior art keywords
alkyl
compound
disease
deficiency
mitochondrial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016503226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514697A5 (enExample
Inventor
アンドリュー ダブリュー． ヒンマン，
アンドリュー ダブリュー． ヒンマン，
ダナ デイヴィス，
ダナ デイヴィス，
ウィリアム ディー． シュレイダー，
ウィリアム ディー． シュレイダー，
Original Assignee
エジソン ファーマシューティカルズ， インコーポレイテッド
エジソン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エジソン ファーマシューティカルズ， インコーポレイテッド, エジソン ファーマシューティカルズ， インコーポレイテッド filed Critical エジソン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2016514697A publication Critical patent/JP2016514697A/ja
Publication of JP2016514697A5 publication Critical patent/JP2016514697A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
JP2016503226A 2013-03-15 2014-03-14 酸化ストレス障害の処置のためのフェナジン−３−オンおよびフェノチアジン−３−オン誘導体 Pending JP2016514697A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/838,372 2013-03-15
US13/838,372 US20140275045A1 (en) 2013-03-15 2013-03-15 Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
PCT/US2014/029811 WO2014145119A1 (en) 2013-03-15 2014-03-14 Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders

Publications (2)

Publication Number Publication Date
JP2016514697A true JP2016514697A (ja) 2016-05-23
JP2016514697A5 JP2016514697A5 (enExample) 2017-04-27

Family

ID=50680171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503226A Pending JP2016514697A (ja) 2013-03-15 2014-03-14 酸化ストレス障害の処置のためのフェナジン−３−オンおよびフェノチアジン−３−オン誘導体

Country Status (6)

Country Link
US (1) US20140275045A1 (enExample)
EP (1) EP2970151A1 (enExample)
JP (1) JP2016514697A (enExample)
CA (1) CA2906154A1 (enExample)
HK (1) HK1220450A1 (enExample)
WO (1) WO2014145119A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019093379A1 (ja) 2017-11-07 2019-05-16 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2610152C (en) 2005-06-01 2018-04-10 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EP3018122B1 (en) 2007-11-06 2018-10-10 BioElectron Technology Corporation 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
CA2708961C (en) 2008-01-08 2017-03-28 Ptc Therapeutics, Inc. (het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
BRPI0918139B1 (pt) 2008-09-10 2024-04-30 Ptc Therapeutics, Inc Composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos
CN102264730B (zh) 2008-10-28 2016-04-13 爱迪生药物公司 用于生产生育三烯酚及衍生物的方法
JP2012525399A (ja) 2009-04-28 2012-10-22 エジソン ファーマシューティカルズ， インコーポレイテッド トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
CA2906145A1 (en) 2013-03-15 2014-09-18 Ptc Therapeutics, Inc. Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
WO2016100579A1 (en) 2014-12-16 2016-06-23 Edison Pharmaceuticals, Inc., Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
DK3258938T3 (da) * 2015-02-17 2021-02-01 Univ Arizona State Phenothiazinanaloger som mitokondrie terapeutiske midler
CA2976937C (en) 2015-02-17 2023-04-04 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2017106786A1 (en) 2015-12-16 2017-06-22 Bioelectron Technology Corporation Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
CN113024369A (zh) 2015-12-17 2021-06-25 Ptc医疗公司 用于治疗氧化应急障碍的化合物
US12570622B2 (en) 2016-08-25 2026-03-10 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10745366B2 (en) 2016-08-25 2020-08-18 Arizon Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US11390605B2 (en) 2016-08-25 2022-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Substituted pyrimidine compounds as multifunctional radical quenchers and their uses
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
JP7586815B2 (ja) 2018-10-17 2024-11-19 ピーティーシー セラピューティクス， インコーポレイテッド α－シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための２，３，５－トリメチル－６－ノニルシクロヘキサ－２，５－ジエン－１，４－ジオン
CN118175991A (zh) 2021-07-08 2024-06-11 Ptc医疗公司 包含2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮的药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59144774A (ja) * 1983-01-21 1984-08-18 メルク　フロスト　カナダ，インコーポレーテッド フエノチアゾン誘導体及び類似体
WO1984004679A1 (en) * 1983-05-25 1984-12-06 John W Eaton Method and agents for raising animal tolerance to oxidant stress-inducing antibiotics
JPS60209520A (ja) * 1984-03-19 1985-10-22 メルク　エンド　カムパニー　インコーポレーテツド リポキシゲナーゼ阻害剤の細胞保護的使用
WO2012138713A2 (en) * 2011-04-04 2012-10-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Multifunctional radical quenchers for the treatment of mitochondrial dysfunction

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4667032A (en) * 1983-01-21 1987-05-19 Merck Frosst Canada, Inc. Phenothiazone derivatives and analogs
NZ513547A (en) 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
GB0204232D0 (en) 2002-02-22 2002-04-10 Isis Innovation Assay
EP1378753B1 (en) 2002-07-01 2006-05-31 Santhera Pharmaceuticals (Schweiz) GmbH A screening method and compounds for treating Friedreich Ataxia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59144774A (ja) * 1983-01-21 1984-08-18 メルク　フロスト　カナダ，インコーポレーテッド フエノチアゾン誘導体及び類似体
WO1984004679A1 (en) * 1983-05-25 1984-12-06 John W Eaton Method and agents for raising animal tolerance to oxidant stress-inducing antibiotics
JPS60501408A (ja) * 1983-05-25 1985-08-29 イ−トン，ジヨン　ダブリユ−． 酸化剤ストレス誘導抗生物質に対する動物許容度を増加させる方法及び薬剤
JPS60209520A (ja) * 1984-03-19 1985-10-22 メルク　エンド　カムパニー　インコーポレーテツド リポキシゲナーゼ阻害剤の細胞保護的使用
WO2012138713A2 (en) * 2011-04-04 2012-10-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Multifunctional radical quenchers for the treatment of mitochondrial dysfunction

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HASEGAWA, K. ET AL.: "The Carbon-13 NMR Spectra and Electronic Structure of 3H-phenothiazin-3-one and Its Methyl Derivativ", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 57(2), JPN6018002285, 1984, pages 510 - 517, ISSN: 0003726070 *
SUZUKI, JOSEPH K. ET AL.: "The Synthesis of 6,9-Dioxo-, 6,9- and 7,9-Dihydroxychlorpromazines, Possible Metabolites of Chlorpro", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 16(6), JPN6018002286, 1979, pages 1227 - 1232, ISSN: 0003726071 *
UENO, Y.: "Synthesis of Dimethyl- and Trimethyl-3H-phenothiazin-3-ones", PHARMAZIE, vol. 39(5), JPN6018002288, 1984, pages 355 - 356, ISSN: 0003726072 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019093379A1 (ja) 2017-11-07 2019-05-16 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
US11369615B2 (en) 2017-11-07 2022-06-28 Jichi Medical University Agent for improving mitochondrial dysfunction, preventative or therapeutic agent for diseases or symptoms caused by mitochondrial dysfunction, and applications therefor

Also Published As

Publication number Publication date
HK1220450A1 (zh) 2017-05-05
WO2014145119A1 (en) 2014-09-18
EP2970151A1 (en) 2016-01-20
CA2906154A1 (en) 2014-09-18
US20140275045A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
JP2015533794A (ja) 酸化ストレス障害を処置するためのベンゾキノン誘導体
JP2016520621A (ja) 酸化ストレス障害の処置のためのカルボン酸誘導体
US9296712B2 (en) Resorufin derivatives for treatment of oxidative stress disorders
JP5798481B2 (ja) 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体
US9868711B2 (en) Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
JP2016515526A (ja) 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体
JP6045494B2 (ja) ナフトキノンによるミトコンドリア病の処置
CA2906154A1 (en) Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
JP6810692B2 (ja) （ｒ）−２−ヒドロキシ−２−メチル−４−（２，４，５−トリメチル−３，６−ジオキソシクロヘキサ−１，４−ジエニル）ブタンアミドの多形性形態および非晶質形態
US9670170B2 (en) Resorufin derivatives for treatment of oxidative stress disorders
WO2010014758A1 (en) Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress
WO2012174286A1 (en) Catechol derivatives for treatment of oxidative stress diseases

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170323

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180419

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180810